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Background and Aims. To investigate the behaviour of miR-19a and miR-20a, two microRNAs involved in posttranscriptional
modulation of TF expression in peripheral bloodmononuclear cells (PBMCs) exposed to high glucose (HG) and lipopolysaccharide
(LPS), and to evaluate the involvement of angiotensin II in that process. Methods. TF Procoagulant Activity (PCA, one-stage
clotting assay), antigen (Ag, ELISA), and miR-19a and miR-20a levels (specific TaqMan MicroRNA Assays) were evaluated in
PBMCs exposed to high glucose (HG, 50mM), LPS (100 ng/mL), and Olmesartan (OLM, 10−6M), an angiotensin II type 1 receptor
antagonist. Results. HG increased TF expression and decreased both miRs as compared to control glucose conditions (11.1mM). In
HG-activated PBMCs, LPS stimulated TF expression and downregulated miR-20a, an effect reverted by OLM (10−6M); miR-19a
expressionwas unchanged by LPS in bothCG andHG conditions.Conclusions. miR-19a andmiR-20a are inhibited by inflammatory
stimuli active on TF expression and their response differs by the stimulus under investigation; angiotensin II may participate in
that mechanism.
1. Introduction
MicroRNAs (miRs) are small, ∼22-nucleotide noncoding
RNAs that inhibit transcriptional gene expression by inter-
acting with sites of complementarity in the 3󸀠 untranslated
regions (3-UTR) of target mRNAs [e.g., [1]]. Posttranscrip-
tional gene modulation by miRs involves several genes
including Tissue Factor (TF) [2], the principal initiator of the
clotting cascade, and a major regulator of haemostasis and
thrombosis [3] expressed by circulating monocytes exposed
to proinflammatory stimuli such as lipopolysaccharide (LPS,
endotoxin) [3] and high glucose (HG) [4]. Locally generated
angiotensin (AT)II, the effector arm of the renin angiotensin
system (RAS), contributes actively to that inflammatory
process [5], a mechanism downregulated by ATII type 1
receptor (AT1R) blockade [4, 5].
Among other potentially significant miRs interacting
with TF gene [2], miR-19a and miR-20a have recently been
shown to modulate TF expression in monocytes of pa-
tients with immune-mediated diseases [6].That information,
obtained in a very specific context, raises the issue of the
behaviour of those two noncoding RNAs in response to
stimuli active on TF expression in peripheral bloodmononu-
clear cells (PBMCs) harvested fromnormal subjects activated
by HG and LPS and whether ATII is involved in that
relationship, an issue that has never been addressed insofar.
2. Materials and Methods
2.1. Cell Isolation and Culture. Human PBMC suspensions
were obtained from unpooled buffy coats left over from
blood bank draws taken from healthy donors, kept at room
temperature, and utilized within a maximum of 4 hours
from withdrawal. As detailed elsewhere [4], leukocytes were
isolated from fresh buffy coats diluted 1 : 1 with sodium citrate
0.38% in saline solution, mixed gently with 0.5 volume of 2%
Dextran T500, and left for 40min for erythrocyte sedimen-
tation. The leukocyte-rich supernatant was recovered and
centrifuged for 10min at 200×g. The pellet was resuspended
in 30mL of sodium citrate solution, layered over 15mL of
Ficoll-Histopaque, and centrifuged for 30min at 400×g at
20∘C. The PBMC-rich ring was recovered, washed twice in
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sodium citrate 0.38%, and resuspended in polypropylene
tubes in RPMI 1640 medium supplemented with 100U/mL
penicillin-streptomycin.
Glucose perturbation was induced by supplementing
PBMC cultures with D-glucose to reach a final concentration
of 50mM (from now on referred to as high glucose (HG))
to be compared with cells cultured in unsupplemented RPMI
1640 medium containing 11.1mM D-glucose (from now on
referred to as control glucose (CG)). Previous studies had
excluded interferences derived from hypertonicity [4].
Drugs were kept in stock solution and diluted in serum-
free RPMI at the appropriate concentrations immediately
before use. Cell viability, as assessed by dimethyl thiazolyl
diphenyl tetrazolium (MTT), was verified (>85% of viable
cells) throughout all experimental phases.
The final PBMC preparations typically contain 25–35%
monocytes, negligible proportions of neutrophils (<5%), and
65–75% lymphocytes.
All reagents and solutions used for cell isolation and cul-
ture were prepared with endotoxin-free water and glassware
was rendered endotoxin-free by exposure to high tempera-
ture. Drugs were kept in stock solution and diluted in serum-
free RPMI at the appropriate concentrations immediately
before use.
Confounding from interindividual differences in TF sen-
sitivity to proinflammatory stimuli was avoided by using
unpooled buffy coats of the same subject throughout the
different phases of the experimental series.
2.2. TF Procoagulant Activity (PCA). PCA was assessed by
one-stage clotting time in PBMCs disrupted by three freeze-
thaw cycles as described in [4]. Time to clot formation
was recorded and values converted to arbitrary units (AU)
by comparison with a standard human brain TF calibra-
tion curve covering clotting times from 20 to 600 s. The
standard TF preparation was arbitrarily assigned a value
of 1000AU/mL and a representative conversion of clotting
times to AU is as follows: 100AU-21 s, 10 AU-40 s, 1 AU-82 s,
0.1–187 s, 0.01 AU-375 s, and 0.001 AU- 600 s. Experiments
were run in triplicate and averaged.
2.3. TF Antigen (Ag). Cells were disrupted by three repeated
freeze-thaw cycles and TF extracted with a buffer of Tris
buffered saline (50mM Tris, 100mM NaCl, pH 7.4) con-
taining 0.1% Triton X-100. After an overnight extraction,
the debris was pelleted by centrifugation at 100×g for 1 h
at 4∘C and supernatants were used for ELISA (Imubind TF
kit Sekisui Diagnostics, West Malling, United Kingdom).
TF Ag levels were expressed in pg/mL using a reference
curve created by the TF standards. Within and between assay
variability were 3.5 and 5.5%, respectively.
2.4. miRs Expression. Total RNA including miRs was iso-
lated from PBMCs using the miRNeasy Mini Kit (Qiagen),
according to the manufacturer’s instructions. RNA samples,
after quality and quantity evaluation using a NanoDrop ND-
1000 spectrophotometer, were stored at −80∘C until used in
the experiments. Quantification of miR-19a, miR-20a, and
RNU6B (as housekeeping gene) expressionwas carried out in
triplicate using specific TaqMan MicroRNA Assays (Applied
Biosystems), according to the manufacturer’s instructions.
Briefly, 10 ng of RNA was retrotranscribed by the Taq-Man
MicroRNA Reverse Transcription (RT) Kit (Applied Biosys-
tems) using individual miR-specific RT primers, and 1.3 𝜇l
of RT product was analyzed by quantitative Real Time-PCR
(qRT-PCR) on the Rotor-Gene 6000 (Corbett Research).
Threshold cycle (Ct) and baselines were determined by
manual settings. miR expression was calculated by relative
quantification and fold expression changes were determined
by the 2−ΔΔCt method using the DataAssistTM software
(Applied Biosystems). miR changes were analyzed as percent
changes from either CG or HG used as referents.
TF PCA and Ag and miR levels were assayed after a 18 hr
and 2 hr incubation interval, respectively. PCA, ELISA, and
qRT-PCR results in both control and experimental groups
were obtained from suspensions containing equal number of
cells (3 × 106 PBMCs/mL).
2.5. Experimental Design. The study included two series of
experiments. The first series (𝑛 = 4) evaluated the effect
on miR-19a and miR-20a and TF expression of HG versus
CG and the second one (𝑛 = 9) evaluated the effect of LPS
(100 ng/mL) stimulation on PBMCs incubated in CG or HG
conditions, either per se or in presence of Olmesartan (OLM)
(10−6M), an ATII type 1 receptor (AT1R) antagonist [7].
2.6. Statistics. Statistical differences were tested by Wilcoxon
test for paired comparisons on absolute data (TF PCA
and Ag) or percent changes (miR expression) from control
conditions normalized to 100%. Data were reported as means
± SD and a two-tailed 𝑝-level <0.05 was the threshold for
statistical significance.
3. Results
As compared with CG, HG inhibited miR-19a and miR-20a
expression and induced a highly significant stimulation of
both TF PCA and TF Ag (Figures 1(a) and 1(b)).
LPS increased TF PCA and TF Ag in both CG and HG
conditions (Figures 2(a) and 3(a)). In CG conditions, miR-
20a levels in response to LPS showed inconsistent changes
but decreased in presence of HG, a trend reverted by AT1R
blockade through OLM (Figures 2(b) and 3(b)).
miR-19a levels were insensitive to LPS stimulation in
either of experimental conditions (Figures 2(b) and 3(b)).
4. Discussion
This study shows inhibition of both miR-19a and miR-
20a in response to HG [4], a procoagulant [4, present
results] and proinflammatory stimulus [8–10] that activates
NF-𝜅B [10, 11], a redox-sensitive transcription factor [12]
critical for TF gene expression [3]. Notably, cytoplasmicmiR-
induced silencing complexes restrain TF protein transla-
tion and destabilize TF mRNA by binding to the 3󸀠-UTR
of TF transcripts [1] and binding sites for both miR-19a
and miR-20a have been recognized in the 3󸀠-UTR of the
TF mRNA transcript in human monocytes [6] and other
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Figure 1: (a) High glucose (HG, 50mM)-induced stimulation of TF PCA (left ordinate, log scale) and TF Ag (right ordinate). (b)
Downregulation of miR-20a and miR-19a expression in response to HG as compared with control glucose (CG, 11.1mM). Means ± SD;
𝑁 = 4, ∗𝑝 < 0.001HG versus CG.
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Figure 2: (a) LPS (100 ng/mL)-induced stimulation of TF PCA (left ordinate, log scale) and Ag (right ordinate) downregulated by AT1R
blockade through Olmesartan (OLM, 10−6M). PBMCs incubated in control glucose (CG, 11.1mM). (b) Percent changes of miR-20a and miR-
19a in LPS-stimulated PBMCs per se or in presence of OLM (10−6M). Data expressed as percent changes from CG. Means ± SD, 𝑁 = 9.
&𝑝 < 0.001 LPS versus CG; ∗𝑝 < 0.001 OLM + LPS versus LPS.
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Figure 3: (a) LPS (100 ng/mL)-induced stimulation of TF PCA (left ordinate) (note the scale difference with the same parameter reported in
Figure 2) and Ag (right ordinate) downregulation by AT1R blockade through Olmesartan (OLM, 10−6M); PBMCs incubated in high glucose
(HG, 50mM). (b) Percent changes of miR-20a andmiR-19a in LPS-stimulated PBMCs per se or in presence of OLM (10−6M). Data expressed
as percent changes from HG. Means ± SD,𝑁 = 9. &𝑝 < 0.001 LPS versus HG; ∗𝑝 < 0.001 LPS + OLM versus LPS.
cell types as well [13, 14]. Therefore, downregulated miRs
expression by HG may conceivably facilitate HG-induced
TF expression, a mechanism possibly contributing to the
hypercoagulable state induced by high blood glucose in
diabetic patients [15]. However, our PBMCs were perturbed
by glucose concentrations far beyond that reached clin-
ically and, therefore, the present results are to be seen
as preliminary observations awaiting further validation in
more physiological conditions. Moreover, we carried out
these experiments in cell lysates, a preparation differing in
several ways from intact cells such as, for example, amplifi-
cation of procoagulant responses due to exposure of anionic
phospholipids from disrupted membranes [16]. Therefore,
the present results may not necessarily be extrapolated to
intact PBMC, a point that deserves attention in future
studies.
A second result of this study worth of comment relates
to the inhibition by LPS of miR-20a in HG-activated PBMCs,
an effect compatible with attenuation of a negative posttran-
scriptional feedback loop on TF expression in interaction
with HG-induced excess ROS production and NFkB overac-
tivation [8–11]. On the other hand, LPS stimulation did not
change miR-19a levels in our PBMC preparations at variance,
in this respect, with human umbilical vein endothelial cells
(HUVECs), a cell line capable of rapid TF induction [17]
in which endotoxin downregulated miR-19a expression [18].
Thus, the control mechanism of miR-19a may vary according
to the tissue under evaluation, a speculative possibility in
need of experimental verification.
A third and intriguing point emerging from these
results was the reversal of LPS-induced miR-20a down-
regulation by OLM, an AT1R blocker that, as expected
[4, 5], inhibited both TF PCA and TF Ag. That effect,
reminiscent, to some extent, of results reported by other
authors [19], suggests an involvement of ATII in posttran-
scriptional regulation of LPS-induced procoagulant activ-
ity. This speculative possibility adds a new hypothetical
component to the intricate interrelationship between locally
generated ATII and LPS [20–22], a major marker for the
recognition of intruding Gram-negative bacteria by the
innate immune system that initiates the pathogen-induced
inflammatory response [23] of which activation of coagu-
lation is a prominent component [24]. However, any role
of ATII in the posttranscriptional control of inflammation-
induced TF expression is only hypothetical at the moment
and needs further studies including confirmation of the
present findings by using other RAS antagonists such as
ACE inhibitors and ATII receptor antagonists different from
OLM.
5. Conclusions
The results of this study disclose behaviours of miR-19a
and miR-20a potentially involved in the posttranscriptional
regulation of TF expression in the context of the complex
interplay among inflammation, coagulation, and ATII, in
which TF plays a pivotal role.
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